Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis~* Patients with a relapsing-remitting disease course~* Patients with EDSS score of 0-5.5~Exclusion Criteria:~* Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc.~* Pregnant or nursing women~Other protocol-defined inclusion/exclusion criteria applied to this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod 1.25 mg (Type: EXPERIMENTAL): None
- Fingolimod 0.5 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).